MedTrace Logo

Intrapulmonary Pharmacokinetics of Antibiotics

NCT00315601 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2009-02-13

No results posted yet for this study

Summary

The major objectives of this research are to see how much, and for how long, telithromycin and azithromycin get into the fluids and cells of the lung.

Conditions

  • Healthy

Interventions

DRUG

Telithromycin

800 mg once a day for 5 days

DRUG

azithromycin

500 mg on day 1, and then 250 mg once-daily on days 2 through 5

PROCEDURE

bronchoalveolar lavage

One bronchoscopy with bronchoalveolar lavage with each drug administration

DRUG

Telithromycin

Telithromycin 800 mg once a day

Sponsors & Collaborators

  • Sanofi

    collaborator INDUSTRY

  • University of Illinois at Chicago

    lead OTHER

Principal Investigators

  • Keith A. Rodvold, Pharm.D. · University of Illinois at Chicago

  • Mark H. Gotfried, M.D. · Pulmonary Associates, PA

  • Larry H. Danziger, Pharm.D. · University of Illinois at Chicago

Study Design

Allocation
NON_RANDOMIZED
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2006-01-31
Primary Completion
2006-11-30
Completion
2006-11-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00315601 on ClinicalTrials.gov